Full access
Clinical & Research News
Published Online: 3 December 2010

Medication Rare in Addiction Treatment

Publication: Psychiatric News
Volume 45, Number 23
https://doi.org/10.1176/pn.45.23.psychnews_45_23_043
At the recent “New Frontier in Addiction Treatment” conference (see Reform May Jolt Field Plagued By Frustration), Paul Roman, Ph.D., a distinguished research professor of sociology at the University of Georgia, argued that medications used to treat substance abuse, such as naltrexone, acamprosate, and buprenorphine, hold great promise but are “frozen.”
Paul Roman, Ph.D.: “We have failed to educate the public about medication-assisted treatment” for substance abuse.
Credit: Joan Arehart-Treichel
“We have failed to educate the public about medication-assisted treatments, or MAT,” he asserted. “The public doesn't know anything about this stuff. It needs to know something or we are not going to get anywhere with it.” This is especially the case regarding youth with substance abuse problems, he believes.
Only about one-third of substance abuse programs in the United States are using MAT in one way or another, he continued. Usually they are larger programs located in a hospital setting or that have a physician on staff.
But even 41 percent of private substance abuse programs with a physician on staff do not use MAT, and 82 percent of public substance abuse programs with a physician on staff do not do so. Programs that place a strong emphasis on the 12-step model of treatment are significantly less likely to use MAT than other types of programs.
Another barrier to the use of MAT is lack of physician training in how to deploy the medication treatments, Roman pointed out. For example, psychiatrists may need guidance in using injectable naltrexone (Vivitrol).
“We would like to move MAT into primary care,” said Roman, “but that is only a dream at this point. Peter Miller, Ph.D., a professor at the Medical University of South Carolina's Center for Drug and Alcohol Programs, agreed. The larger problem, Miller said, is that detecting or treating alcohol use disorders in primary care is far from routine.
“So is the fact that the glass is only one-third full in terms of using MAT a cause for alarm?” Roman asked. “I don't know,” he said. “We have made progress, but this is a field that remains on the defensive.”

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 45 • Number 23 • December 3, 2010
Pages: 34

History

Published online: 3 December 2010
Published in print: December 3, 2010

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

There are no citations for this item

View Options

View options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.